UNSPSC 51151603: Procyclidine

This classification denotes an antimuscarinic agent with the molecular formula C19H29NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C6QE1Q1TKR, chemically known as 1-pyrrolidinepropanol, alpha-cyclohexyl-alpha-phenyl- but generally known as procyclidine, which bears US NIH Compound Identifier 4919. European Medicines Agency schedules Procyclidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10064MIG. The term PROCYCLIDINE is an International Non-Proprietary Name.

UNSPSC 51151603 Procyclidine is a Commodity code that state and local governments are using to procure naloxone and drug deactivation systems, not procyclidine itself. Recent solicitations show health agencies and state HHS commissions buying pharmaceutical products and pharmaceutical management services related to opioid response and prescription fulfillment. The issuing bodies include county health departments and state-level health and human services agencies. The actual procurement activity centers on naloxone supply contracts with quarterly delivery requirements and exploratory procurement related to direct-to-manufacturer pharmacy initiatives, which diverges substantially from the code's nominal pharmaceutical ingredient classification.

Activity appears concentrated in Florida and Texas. Seminole County, Florida issued IFB60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, with a response deadline of July 26, 2023, and a two-year initial term plus one-year renewal option. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription fulfillment programs, with a response deadline of April 3, 2026, designed to inform future formal solicitation strategy rather than award a contract immediately. Both opportunities required standard vendor compliance including E-Verify, workers' compensation insurance, and drug-free workplace certification. The code shows limited recent activity, and the mismatch between the nominal procyclidine classification and the actual goods being solicited suggests either miscoding or use of the code as a catch-all for pharmaceutical procurement outside traditional drug-ingredient categories.